Clorox (CLX) Rating Increased to Outperform at Consumer Edge

Clorox (NYSE:CLX) was upgraded by equities researchers at Consumer Edge from a “neutral” rating to an “outperform” rating in a research note issued on Friday, November 10th, MarketBeat reports.

A number of other research firms have also issued reports on CLX. Jefferies Group reaffirmed a “hold” rating and set a $132.00 target price (down previously from $137.00) on shares of Clorox in a report on Friday, October 6th. Zacks Investment Research lowered shares of Clorox from a “hold” rating to a “sell” rating in a report on Wednesday, October 4th. Morgan Stanley dropped their price objective on shares of Clorox from $138.00 to $128.00 and set an “equal weight” rating for the company in a report on Thursday, November 2nd. Deutsche Bank reissued a “hold” rating and issued a $137.00 price objective (up previously from $126.00) on shares of Clorox in a report on Saturday, July 22nd. Finally, BidaskClub raised shares of Clorox from a “strong sell” rating to a “sell” rating in a report on Monday, July 31st. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and three have given a buy rating to the company. Clorox presently has a consensus rating of “Hold” and a consensus price target of $128.72.

Clorox (CLX) traded up $2.26 on Friday, hitting $139.22. 1,268,400 shares of the company traded hands, compared to its average volume of 810,485. The company has a debt-to-equity ratio of 3.02, a quick ratio of 0.77 and a current ratio of 1.10. Clorox has a 1 year low of $112.28 and a 1 year high of $141.76. The firm has a market cap of $17,660.00, a PE ratio of 24.40, a P/E/G ratio of 3.69 and a beta of 0.39.

Clorox (NYSE:CLX) last released its earnings results on Wednesday, November 1st. The company reported $1.46 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.41 by $0.05. Clorox had a net margin of 11.84% and a return on equity of 161.59%. The business had revenue of $1.50 billion during the quarter, compared to analyst estimates of $1.48 billion. During the same quarter in the prior year, the firm earned $1.36 earnings per share. The company’s revenue for the quarter was up 4.0% compared to the same quarter last year. analysts forecast that Clorox will post 5.58 earnings per share for the current fiscal year.

In other news, SVP Michael R. Costello sold 10,574 shares of the stock in a transaction dated Tuesday, November 28th. The shares were sold at an average price of $136.01, for a total transaction of $1,438,169.74. Following the sale, the senior vice president now owns 34,867 shares of the company’s stock, valued at $4,742,260.67. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Matthew T. Laszlo sold 20,051 shares of the stock in a transaction dated Wednesday, November 8th. The stock was sold at an average price of $130.46, for a total transaction of $2,615,853.46. Following the sale, the senior vice president now directly owns 10,896 shares in the company, valued at approximately $1,421,492.16. The disclosure for this sale can be found here. Corporate insiders own 1.00% of the company’s stock.

Hedge funds have recently added to or reduced their stakes in the stock. Jacobi Capital Management LLC increased its stake in Clorox by 0.3% in the first quarter. Jacobi Capital Management LLC now owns 1,282 shares of the company’s stock valued at $172,000 after purchasing an additional 4 shares during the last quarter. Valley National Advisers Inc. increased its stake in Clorox by 0.6% in the second quarter. Valley National Advisers Inc. now owns 865 shares of the company’s stock valued at $115,000 after purchasing an additional 5 shares during the last quarter. Bernzott Capital Advisors increased its stake in Clorox by 0.4% in the second quarter. Bernzott Capital Advisors now owns 1,607 shares of the company’s stock valued at $214,000 after purchasing an additional 7 shares during the last quarter. Janney Capital Management LLC increased its stake in Clorox by 0.5% in the second quarter. Janney Capital Management LLC now owns 1,611 shares of the company’s stock valued at $214,000 after purchasing an additional 8 shares during the last quarter. Finally, Financial Advisory Service Inc. increased its stake in Clorox by 0.3% in the second quarter. Financial Advisory Service Inc. now owns 4,012 shares of the company’s stock valued at $535,000 after purchasing an additional 12 shares during the last quarter. Hedge funds and other institutional investors own 73.39% of the company’s stock.

WARNING: “Clorox (CLX) Rating Increased to Outperform at Consumer Edge” was published by BBNS and is the sole property of of BBNS. If you are viewing this article on another website, it was illegally stolen and reposted in violation of US & international copyright law. The legal version of this article can be viewed at https://baseballnewssource.com/markets/clorox-company-the-clx-lifted-to-outperform-at-consumer-edge/1773906.html.

About Clorox

The Clorox Company is a manufacturer and marketer of consumer and professional products. The Company sells its products primarily through mass retail outlets, e-commerce channels, wholesale distributors and medical supply distributors. The Company operates through four segments: Cleaning, Household, Lifestyle and International.

Analyst Recommendations for Clorox (NYSE:CLX)

Receive News & Ratings for Clorox Company (The) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clorox Company (The) and related companies with our FREE daily email newsletter.

 


Latest News

Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Yankees and Marlins Continue Stanton Trade Talks
Yankees and Marlins Continue Stanton Trade Talks
Marlins Making Moves, Trade Dee Gordon to Seattle
Marlins Making Moves, Trade Dee Gordon to Seattle
Report: Astros Dallas Keuchel Pitched With Injured Foot
Report: Astros Dallas Keuchel Pitched With Injured Foot
Angels Sign Former Prospect with Braves Kevin Maitan
Angels Sign Former Prospect with Braves Kevin Maitan
Shohei Ohtani Has Turned Down Red Sox and Yankees
Shohei Ohtani Has Turned Down Red Sox and Yankees


Leave a Reply

 
© 2006-2017 BBNS.